5 Key Takeaways

• 1

  Peng Lu highlighted the advancement of the late-stage clinical program for bradykinin-mediated angioedema over the past year.

• 2

  The RAPIDe-3 study provided topline data suggesting that deucrictibant may offer a differentiated profile for treating hereditary angioedema attacks.

• 3

  Peng Lu emphasized the importance of preparing for the submission of the New Drug Application for investigational deucrictibant.

• 4

  Small molecules maintain advantages in oral bioavailability, manufacturing, and reduced immunogenicity compared to newer modalities.

• 5

  The integration of translational science and AI is rapidly evolving, enhancing decision-making and study design in drug development.